1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B9885205B1F8C67D65257FD500370812
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-role-launch-medical-device-companies?opendocument
18
19opendocument
2018.212.222.217
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

Medical Affairs Launch Excellence: Medical Affairs Role at Launch in Medical Device Companies

ID: 5420


Features:

14 Info Graphics

16 Data Graphics

150+ Metrics

2 Narratives


Pages/Slides: 42


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Medical Affairs Launch Excellence: Medical Affairs Role at Launch in Medical Device Companies”

STUDY OVERVIEW

A rapidly changing marketplace coupled with a highly regulated promotional environment have pushed the medical affairs function beyond its traditional support role into a more prominent launch role that extends from the pre-launch phase to well beyond market entry.

Therefore, a successful launch of a new medical device requires deep involvement of medical affairs. In essence, medical affairs launch strategy should focus on early stage thought leader identification and engagement, clear guidance for commercial strategies and launch resources management.

Best Practices, LLC conducted a benchmarking study to highlight the critical success factors for a strong medical affairs launch support, as well as to highlight strategies for thought leader targeting and communication. This study will serve as a reference point for medical device companies in developing successful medical affairs launch strategies.


KEY TOPICS

• Medical Affair’s Role in Launch Activities
• Thought Leader Tiering
• Thought Leader Targeting and MSL Coverage
• Launch Investment
• Medical Affairs Investment Allocation

KEY METRICS

Total Number of Thought Leaders Targeted and MSLs Employed for a Product during Pre-launch and Post-launch Period
Number of Thought Leaders Targeted per MSL Employed
Total Launch Investment for the Product during Pre-launch and Post-launch Period
Total Number of FTEs Allocated for the Product during Pre-launch and Post-launch Period
Total Medical Affairs Launch Investment per Product Supported During Pre-launch and Post-launch Phase
Medical Affairs Launch Investment Allocated to Listed Medical Affairs Activities During Each Time Period
Medical Affairs Launch FTEs Allocated to Listed Medical Affairs Activities During Each Time Period

SAMPLE KEY FINDINGS

1. Medical Affairs’ Role in Launch Activities: Medical Affairs is heavily involved in five launch activities within participating organizations: Scientific Publications, MSL Activities, Advisory Boards, Thought Leader identification and development and Speaker Training. More than 60 percent of medical device companies are involved in these top 5 activities.

2. Thought Leader Tiering: More than 75 percent of the benchmark class use five criteria while segmenting their TLs in the pre-launch stage: Regional Diversity, Therapeutic Area, Product Types, TLs’ Experience, & TLs’ Expertise.

METHODOLOGY

Best Practices, LLC engaged 14 Medical Affairs leaders at 13 medical device companies through a benchmarking survey. More than 70% of the participants are at the level of VP/CEO/Director and around a quarter of participants are managers.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Manufacturing; Consumer Products; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Axon Pharma; BARD Medical; Baxter International; Bayer; Covidien; Fresenius Kabi; Johnson & Johnson Vision Care; Medtronic; Novo Nordisk; Sanofi; Terumo


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.